Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAPMET: MET Kinase Inhibitors in Metastatic Papillary Renal Carcinoma
NCT02761057Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2016
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of cabozantinib, crizotinib and savolitinib in renal cell carcinoma (RCC) (4 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 3 years. Started Jul 2016; status: completed.
02
Drugs
cabozantinibcrizotinibsavolitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02761057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02761057.